Omnix Medical Announces First Patients Dosed in Phase II Trial of Antimicrobial Lead Compound OMN6
— Novel mechanism of action based on the direct physical elimination of pathogenic bacteria
— First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for severe multidrug-resistant infections, announced today that the first patients in a Phase II trial (NCT06087536)[1] have been dosed with its lead compound OMN6, a first-in-class antimicrobial targeting severe multidrug-resistant Acinetobacter baumannii infections associated with high mortality and limited treatment options. Read more…
MetrioPharm AG: Prof. Dr. med. Jürgen Braun Appointed as New Member of the Scientific Advisory Board
— Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG.
— With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.
MetrioPharm AG, a clinical-stage biotechnology company developing medicines for inflammatory and infectious diseases, today announced that Prof. Dr. med. Jürgen Braun is joining the company’s Scientific Advisory Board.
With the appointment of Prof. Braun, MetrioPharm is specifically expanding its Scientific Advisory Board with expertise in inflammatory rheumatic diseases such as rheumatoid arthritis.
Mabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical Development
- Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trial
- Funding secured for follow-on tree (Fagales) pollen program MY010
Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing of individuals with peanut allergy in the Phase Ib part of the study. The Company’s antibodies are designed to neutralize disease-relevant allergens, thereby preventing allergic reactions.
